FILE-A person uses Wegovy for weight loss. (Photo by Steve Christo – Corbis/Corbis via Getty Images)
<!–>
–> <!–>
Obesity is among the significant health issues in the U.S. and there are methods that some people use to assist them in their quest to shed pounds.
Anti-obesity medications are one of the products used to help individuals achieve their weight loss goals, but a recent study reveals that weight may return weeks after you no longer use the drugs.
–>
RELATED: Popular weight loss drugs could help with alcohol, opioid addictions: study
In a study published in BC Medicine, researchers examined data for patients receiving anti-obesity medications (AOMs) or weight loss drugs across 11 clinical trials. Their findings imply that while the amount of weight regain differs depending on the type of anti-obesity drug, there is a general trend associated with weight regain after the medication is no longer used.
<!–>
How was the data gathered for the study?
–>
Dig deeper:
<!–>
Scientists assessed data from 1,574 people in treatment groups and 893 in control groups. Their weight change was measured by changes in body weight and body mass index (BMI) after they stopped using the anti-obesity medication (AOMs).
–>
RELATED: Zepbound vs. Wegovy: Here’s which weight loss drug worked best in first trial
<!–>
When performing their evaluations of the patients, the team considered factors like the kind of anti-obesity medication, the presence of diabetes, and the individuals’ lifestyles in terms of their diet and exercise habits.
–>
According to the study, researchers discovered that AOMs were connected to substantial weight loss in patients that used them. However, the patients started to regain weight eight weeks after no longer using AOMs.
<!–>
The study found that the amount of weight patients regained was based on several key contributors, like the type of anti-obesity medication they were using and changes in their lifestyle.
–>
What are researchers saying about their findings?
<!–>
Big picture view:
–>
The study noted there are currently six medications (orlistat, naltrexone-bupropion, liraglutide, semaglutide, tirzepatide, and phentermine-topiramate) approved for the treatment of obesity in adults.
<!–>
Researchers concluded in their report that significant weight regain happened eight weeks after patients on anti-obesity medications (AOMs) and were sustained for 20 weeks.
–>
Additionally, different weight regain was observed in people with distinctive characteristics. The team explained that studies with longer follow-up duration are needed to continue investigating possible factors linked with weight change after stopping the use of AOMs.
<!–>
The Source: Information for this story was provided by a study published in BC Medicine. This story was reported from Washington, D.C.
–>